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The regulatory framework of biosimilar products in Korea is a 3-tiered system: 1) Pharmaceutical Affairs
Act; 2) Notiﬁcation of the regulation on review and authorization of biological products; 3) Guideline on
evaluation of biosimilar products. A biosimilar product is regulated under the same regulation as bio-
logical products. The difference from new biological product is that biosimilar product requires full
comparability data with reference product. Based on these data, some of the non-clinical and clinical
data could be abbreviated. As Korean guideline for biosimilar products was developed along with that of
the WHO’s, most of the recommendations were based on similar principle except the clinical evaluation
to demonstrate similarity. No biosimilar products are licensed yet, however, 4 IND products have been
approved for phase I or III clinical trials. The addressed issues during review were as follows: accept-
ability of reference products manufactured in different sites, determination of acceptable criteria for
differences and selection of analytical tests for the comparability exercise to detect potential differences
in quality attributes, relevant species for non-clinical study, and duration of toxicity study, etc. These and
other future issues will be dealt with scientiﬁc advancement, experiences of collaborating work with
WHO or other NRAs, which will be reﬂected in the guidelines on regulations of biosimilar products in
Korea.
 World Health Organization 2011. All rights reserved. The World Health Organization has granted the
Publisher permission for the reproduction of this article.1. Introduction (legislative basis)
Biotherapeutic products, as opposed to chemical drugs are large,
complex molecules produced using complex manufacturing
processes. This contributes to the high costs associated with these
highly successful medicines. The mean growth of top 8 bio-
therapeutics such as Humira, Lantus, Herceptin, Neulasta, Avastin,
Enbrel, Rituxan, insulinwas estimated to bemore than 250% during
2004e2007, which is very high compared with 50% growth for the
top 8 small molecules [1]. The total global market for protein drugs
was $47.4 billion in 2006, which is estimated to reach $55.7 billion
by the end of 2011, an average annual growth rate of 3.3% [2].
Because of the high daily treatment costs of biopharmaceuticals,
there is an increasing need for reducing the medical insurance and
costs by providing access to copy or similar versions of blockbuster
biological products such as Erythropoietin, interferon-b, TNF
antagonists where patents have expired or are expiring in the near
future. Consequently, biopharmaceutical companies are trying to
develop copy versions of biological products. Although these: þ82 43 719 3500.
zoo65@gmail.com, parkzoo@
ll rights reserved. The World Healthproducts are based on the same gene sequence as originator
product, the production system and puriﬁcation processes are
probably different. Because of the complexity associated with bio-
therapeutic products (e.g., high molecular weight, three-
dimensional structure, complex manufacturing process), which
results in a product which is dissimilar in characteristics, biological
activity, safety, efﬁcacy, and immunogenicity in comparison with
the original product [3,4], the generic approach in both develop-
ment and review of these products is not appropriate. Another
approval track (the biosimilar pathway) for them has been
prepared in NRAs including Korea where demonstration of simi-
larity in terms of quality, safety and efﬁcacy is essential.
In Korea, the high level regulation to license the drug or bio-
logical products is the same. All products are subject to the “Phar-
maceutical Affairs Act”. As a lower level regulation, there are KFDA
notiﬁcations. Drugs and biological products including bio-
therapeutics comply with their own notiﬁcation. “Notiﬁcation of
the regulation on review and authorization of biological products”
are for biological products, and biosimilar products too. In 2009,
biosimilar product was deﬁned in Korea as biological products that
are proved to be comparable to already marketed reference prod-
ucts in terms of quality, safety, and efﬁcacy in the above regulation.
The requirements for biosimilar products were detailed inOrganization has granted the Publisher permission for the reproduction of this article.
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was developed along with that of WHO’s [5,6]. Most of the
recommendations are “similar” except the clinical evaluation to
demonstrate similarity. Reference product is deﬁned as a biological
product already approved by a regulatory authority on the basis of
full registration dossier (licensed based on full quality, safety, and
efﬁcacy data).
2. Korean biosimilar guideline
2.1. Scope
In the Korean pharmaceutical regulation, the deﬁnition of
a biosimilar product is a biotechnological product that is proved to
be comparable to an already approved reference product in terms
of quality, non-clinical and clinical evaluation. The scope of bio-
similar products is applied to well-characterized recombinant
protein products.
2.2. General consideration
The scientiﬁc principle of a biosimilar approach is that the
existing generic deﬁnition is not appropriate for biosimilars due to
the complexicity of biotechnology products. Therefore, approval of
a biosimilar product should be based on the demonstration of
similarity of quality, efﬁcacy and safety to a reference drug with
comprehensive comparative data. The purpose of comparability
exercise is to demonstrate that the quality of a biosimilar product is
highly similar to a reference drug and to make sure there is no
adverse impact on efﬁcacy and safety. In other words, biosimilar
products are not merely expected to demonstrate the safety and
efﬁcacy of itself, but to demonstrate an absence of clinically
meaningful differences to the reference product. Reduction in the
non-clinical and clinical data could be possible through compre-
hensive characterization and comparison at quality level. In the
development of a biosimilar product, a stepwise approach of
comparability exercise is recommended, beginning with quality
studies and followed by non-clinical and clinical studies. An
important point to emphasize is that if the biosimilar manufacturer
cannot demonstrate the similarity of a biosimilar product and
a reference product, the approval process would be required to
follow the stand-alone pathway as a new product application, and
it cannot be called nor classiﬁed as a biosimilar product. The stand-
alone pathway for a new product application requires a complete
data package. In addition, an ‘abbreviated pathway’ requiring full
quality assessment of the products, a reduced package of non-
clinical data, and comparative clinical studies with comparators
for each indication is also an option. As mentioned above, the
products licensed using this pathway are not biosimilars. Regula-
tory decision making should be based on science and regulatory
principles existing within their jurisdictions.
2.3. Reference drug
A “reference product” is a drug product already approved by
a regulatory authority on the basis of full regulatory dossier
submission. The reference product is used in demonstrating the
comparability of a biosimilar product through quality, non-clinical
studies and clinical studies. In addition, the dosage form, strength,
and route of administration of the biosimilar products should be
the same as that of the reference product. And, a biosimilar product
should not be used as a reference drug. However, if a company
cannot resource a reference product in the Korean market, the
reference product from another country could be acceptable, based
on the approval information of the reference product and thedemonstration of similarity between the biosimilar product and
the reference product.
2.4. Requirements for quality studies
The key issue in quality study is ‘how similar is similar’ because
a protein drug cannot be characterized completely by physi-
ochemical methods, which has the potential to affect the efﬁcacy.
Full CMC dossier with comparability exercise data are required,
including extensive side by side characterization, physicochemical
properties, biological activity, immunochemical properties, impu-
rities and purities, speciﬁcation, and stability. Analytical techniques
should utilize state of the art technologies capable of detecting
slight differences in quality attributes. The impact of observed
differences in the quality attributes should be assessed and then
non-clinical and clinical studies should be designed and conducted
on the basis of the results. Acceptance criteria in setting up the
speciﬁcation should be established and justiﬁed based on the data
obtained from analyses using a number of representative lots of
both reference and biosimilar products.
2.5. Requirements for non-clinical studies
The reduction of non-clinical studies depends on the degree of
similarity in quality. Non-clinical studies should be designed to be
comparative in nature. In vitro studies such as a receptor binding
study and cell proliferation assays are required. In vivo studies and
biological/pharmacodynamic studies are required as well. For the
toxicity studies, at least one repeated dose toxicity study in relevant
species, including a toxicokinetic study and antibody measurement
is needed. Generally, other routine toxicological studies such as
safety pharmacology and reproduction toxicology studies are not
required unless indicated by results from repeat dose studies.
2.6. Requirements for clinical studies
Clinical data requirements include pharmacokinetic studies and
pharmacodynamic studies, and clinical efﬁcacy & safety trials, or
conﬁrmatory PK/PD studies. Clinical studies are required to conduct
in a comparative manner, depending on the data in terms of quality
and non-clinical studies. In clinical comparability exercises, a step-
wise approach is recommended, which means comparative clinical
studies should beginwith PK and PD studies followed by the pivotal
clinical trials. In the design of clinical trials, equivalence trials are
preferable, and equivalence margins should be pre-speciﬁed and
justiﬁed. Extrapolation to other indications of the reference drug
may be possible if similar efﬁcacy and safety has been demon-
strated for a particular clinical indication. Despite the fact the
efﬁcacy can be comparable, the biosimilar can show differences in
the safety proﬁle in terms of severity or adverse events incidence.
Immunogenicity studies are required before approval and even
after approval.
3. KFDA activities related to biosimilars
Korea Food and Drug Administration has actively promoted
a public dialog on the biosimilar issues, because there are many
challenging scientiﬁc and policy related questions about biosimilar
products. In 2008 and 2009, KFDA held two public meetings and
co-sponsored a workshop, in collaboration with stakeholders, to
gather input on scientiﬁc and technical issues. These meetings
resulted in a number of comments and concerns from the inter-
ested parties. KFDA established a regulatory and legislative
pathway for the approval of biosimilar products in 2009 and
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IND submissions for biosimilar products, as of November, 2010.4. Issues on clinical evaluation of biosimilar products
4.1. Reference drug
One of the challenging points in a global development programof
biosimilar products is that it is not possible to conﬁrm whether the
reference product marketed in one region complies with the
requirements in other regions. When NRA requires the reference
product to be sourced from within its jurisdiction, it results in
duplication of clinical studies in each region. A biosimilar manufac-
turer should give a clear justiﬁcation for choice of reference product.4.2. Clinical trials
The clinical study design depends on several different factors
including:
 Treatment practices with reference products may have
changed and effect on clinical study design and recruitment
 Clinical endpoints are difﬁcult to choose; choice of appropriate
clinically relevant endpoints or surrogate markers is important
 Cross-over studies may not be appropriate for protein thera-
peutics with a long half-life as they can have carry-over effects,
or antibodies against the product
 Patient population may affect sensitivity; adequately sensitive
populations to detect a clinically meaningful difference
 Setting a relevant similarity margin; equivalence trials may
need to be very large. Usually, narrow equivalence margins
require huge clinical trial sizes. So, there is a need to agree on
an acceptable equivalence margin based on relevant clinical
and statistical consideration.4.3. Extrapolation of indication
The rationale is that if the biosimilars shows adequate compa-
rability to the reference product for one indication, it may be
reasonable to extend the approval of the biosimilar to all the
indications of the reference product providing the mechanism of
action is the same. A potential concern with the concept of data
extrapolation is that the risks for using a biopharmaceutical may
differ in various patient populations. So, there is a need to have
a more comprehensive and accurate approach to specify which
data are based on extrapolation.4.4. Post-marketing pharmacovigilance
Usually, pre-approval clinical safety data are insufﬁcient to
identify all the potential safety proﬁles, and post-marketing
surveillance including an immunogenicity study is required.
Therefore, there is an opportunity for international cooperation and
exchange of information between regulatory agencies.
5. Further implementation of biosimilar guideline
Regulation and overall guideline for biosimilar products have
been prepared in Korea. However, review and approval of bio-
similar products will be one of the major challenges, because of
little experience of reviewing those, issues that are not solved, rapid
advancement of science, lack of resources etc. Further efforts should
be focused on our capacity building, expertise, collaboration with
other NRAs or WHO to promote global consensus on the regulation
of biosimilar products. Along with this, product based Korean
biosimilar guidelines such as for EPO, G-CSF, and interferon will be
prepared as needed. Guidelines on mAbs regarding characteriza-
tion, manufacturing and control plan to be drafted, as biosimilar
products for mAbs are under active development. Registration of
biological products such as interferon, G-CSF in the Korean Phar-
macopeia is also planned.
6. Conclusions
In conclusion, the rapidly evolving regulatory science in the
biosimilar area would beneﬁt from better cooperation, information
exchange and collaboration from different NRAs. It is important for
all NRAs to work together to have proper regulatory oversight on
the clinical use of biosimilar products. KFDA, as a regulatory
authority, will keep up with the updates and scientiﬁc advances,
which will facilitate access to biosimilar products which are
authorized as safe and effective for use.
Conﬂict of interest
Authors have disclosed no potential conﬂicts of interests.
References
[1] Michael Rice, Biologics insight brieﬁng/deﬁned health/Feb.2009, http://
knowledgebase.deﬁnedhealth.net/?p¼115.
[2] BCC Research, The market for bioengineered protein drugs, 2007/01, http://
www.bccresearch.com/report/bioengineered-protein-drugs-bio009e.html.
[3] The FDA’s assessment of follow-on protein products: a historical perspective.
Nature Review Drug Discovery 2007 Jun;6(6):437e42.
[4] Schellekens H. Follow-on biologics: challenges of the ‘next generation’.
Nephrology Dialysis Transplantation 2005;20(Suppl. 4):iv31e6.
[5] WHO guidelines on evaluation of similar biotherapeutic products (SBPs), http://
who.int/biologicals; October 2009.
[6] Korean guidelines on the evaluation of biosimilar products, http://www.kfda.
go.kr/index.kfda?mid¼226&pageNo¼1&seq¼388&cmd¼v; July 2009.
